Bausch Health Companies (TSE:BHC) Shares Down 0.7% - Here's Why

Key Points

• Bausch Health shares fell 0.7% to C$9.03, with trading volume 24% below the average daily level. The company’s market capitalization is approximately C$3.38 billion.
• Jefferies upgraded the stock to “Hold,” aligning with the consensus rating from three analysts.
• For the latest quarter, Bausch Health reported C$1.79 in EPS and C$4.05 billion in revenue, but posted a negative net margin of 12.02%.

Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s share price dropped 0.7% during trading on Friday. The stock traded as low as C$8.69 and last traded at C$9.03. 407,227 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 537,914 shares. The stock had previously closed at C$9.09.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a "hold" rating in a research note on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to MarketBeat, the company presently has a consensus rating of "Hold".

Bausch Health Companies Trading Down 0.7%

The stock has a market cap of C$3.38 billion, a P/E ratio of -3.07, a PEG ratio of 0.21 and a beta of 0.82. The firm's fifty day moving average price is C$8.66 and its two-hundred day moving average price is C$7.86. The company has a debt-to-equity ratio of -1,173.29, a current ratio of 1.44 and a quick ratio of 0.58.

Bausch Health Companies (TSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. The company had revenue of C$4.05 billion for the quarter. As a group, equities research analysts forecast that Bausch Health Companies Inc. will post 5.55 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc NYSE: BHCTSX: BHC is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.